MDBH News & Events

MDB Capital Holdings announced key leadership transitions within its board of directors. Matthew Hayden will step down from the board effective June 30 to assume a newly created role as Entrepreneur in Residence. Additionally, current board director Dan Torpey has been appointed Chair of the Audit Committee, effective February 13. Torpey joined the Audit Committee in June 2024.

ClearSign Technologies (CLIR) announced that the Company's Board of Directors has voted to expand in size from five to seven directors and it appointed Anthony DiGiandomenico and Lou Basenese to fill such newly created vacancies and to serve as members of the Board, effective as of May 22. Further, on May 27 David M. Maley, a member of the Board, notified the Company that he will not stand for re-election upon the expiration of his term at the Company's 2025 annual meeting of stockholders. The Board has not yet determined whether it will reduce its size or nominate a replacement director at this time. DiGiandomenico has been working with and enabling investment into early-stage disruptive technologies for most of his career. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology, and renewable energy spaces. DiGiandomenico currently serves as the Chief of Transactions and director of MDB Capital Holdings (MDBH), a broker-dealer and financial advisory firm based in Dallas, Texas, which he co-founded in 1997 as MDB Capital Group. Previously, he has served on the board of directors of Provention Bio a developer of multiple drug therapies, from January 2017 until May 2020 and the board of directors of Cue Biopharma, a company that develops novel biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders, from January 2016 to October 2019. Lou Basenese brings over 25 years of experience in equity research and analysis, investment banking, strategic planning, thought leadership development and communications. Basenese currently serves as Executive Vice President - Market Strategy for Prairie Operating (PROP), a Houston-based publicly traded independent energy company engaged in the development and acquisition of oil and natural gas resources in the US.

"Despite the market volatility and cautious investor climate, we are seeing a steady flow of micro-cap companies with really exciting technologies that want to go public but have been unable to get the right partner to get them there. During first quarter, we have continued to work on a robust pipeline of new opportunities in the final stages of diligence which will enable us to focus on scaling the number of disruptive technology ideas we turn into valuable public companies this year," said Christopher Marlett, Co-Founder and CEO of MDB Capital Holdings.

eXoZymes Inc. (EXOZ) and MDB Capital Holdings (MDBH) announced key leadership changes within the eXoZymes board of directors. Mo Hayat has transitioned out of his roles as Chairman of the Board and President of eXoZymes, to focus on new MDB Capital ventures. Edgardo Rayo will join the board on behalf of MDB Capital, making it a full circle moment, as he was the MDB Capital team member who discovered the team of scientific co-founders at UCLA and recognized the transformative potential of the science that ultimately evolved into eXoZymes. Christopher Marlett, CEO of MDB Capital and a current board member of eXoZymes, will assume the role of Chairman to ensure the help and support that MDB Capital will continue to provide eXoZymes.